ArticleEndocrine2022
Lymph node ratio in lateral neck is an independent risk factor for recurrence-free survival in papillary thyroid cancer patients with positive lymph nodes.
Article in Endocrine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- No independent association between lymph node metastasis location and recurrence in papillary thyroid carcinoma: a long-term study.Annals of medicine · 2026Article
- Prognostic Factor Analysis for Risk-Stratified Papillary Thyroid Carcinoma and Nomogram Development for Predicting Structural Incomplete Response to Radioactive Iodine Therapy in Intermediate-Risk Patients.Cancer reports (Hoboken, N.J.) · 2026Article
- Pathological metastatic lymph node density (ND) predicts early recurrence in papillary thyroid cancer patients after curative resection.Gland surgery · 2025Article
- Continuing De-escalation Trends: Is Adjuvant Radioactive Iodine Administration Truly Needed for Papillary Thyroid Carcinoma with Limited Cervical Disease?Annals of surgical oncology · 2025Article
- Nomogram for predicting the risk of cervical lymph node metastases and recurrence in papillary thyroid carcinoma based on the thyroid differentiation score system and clinical characteristics.BMC endocrine disorders · 2025Article
- Risk factor analysis of childhood and adolescent thyroid cancer mediastinal lymph node and distant metastasis.Frontiers in oncology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe purpose of this study was to explore the impact of the lymph node ratio on prognosis in papillary thyroid cancer patients with lymph node metastasis.
methodsData from papillary thyroid cancer patients with positive nodes who were initially treated at our institution during 2015-2016 were analysed. Univariate and multivariate Cox proportional hazard models were adopted to predict prognostic factors. A receiver operating characteristic (ROC) curve was used to find the best cut-off value of the lymph node ratio (LNR). Kaplan-Meier curves were used to show the relationship between the LNR in the lateral neck and recurrence-free survival.
resultsThe median follow-up time was 64.6 months, and recurrence occurred in 16 of 662 patients (2.27%). Univariate analysis showed that male sex, primary tumour size (>17 mm), visible extrathyroidal extension, LNR in the central neck (>0.5), LNR in the lateral neck (>0.10), and visible extranodal extension were significantly correlated with recurrence-free survival (RFS) (p < 0.05). Multivariate analysis using the Cox proportional hazards model showed that the LNR in the lateral neck was an independent risk factor for RFS (p = 0.039; HR 14.76).
conclusionThe LNR in the lateral neck was an independent risk factor for recurrence-free survival. For patients with a high lymph node ratio in the lateral neck, more frequent follow-up might be needed.
Indexed as
Identifiers
36018538What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.